Source: https://www.hairlosshelp.com/html/patentzincoxide.cfm
Timestamp: 2019-09-18 07:59:06
Document Index: 52242598

Matched Legal Cases: ['arts  0', 'arts  1', 'arts  69', 'arts  5', 'arts  3', 'arts  75', 'arts  1', 'arts  9', 'arts  6', 'arts  80', 'arts  1', 'arts  9', 'arts  6', 'arts 81', 'arts 100']

Patent For Zinc Oxide
United States Patent 6,103,273
Antoun August 15, 2000
Pharmaceutical composition comprising starch, a compound comprising boron, a compound comprising zinc, and water, and a method of using same to encourage hair growth
A pharmaceutical composition for the treatment of alopecia areata and male pattern baldness is preferably made from boric acid, zinc oxide, and starch. The method of the present invention comprises applying the pharmaceutical composition of the present invention to a person's scalp. The pharmaceutical composition of the present invention can comprise 10 parts by weight starch, 60 parts by weight boric acid, 40 parts by weight zinc oxide, and 500 parts by weight water. The dry ingredients (starch, boric acid, and zinc oxide) are mixed together, then the water is added. The mixture is boiled for 20 minutes, stirring continuously. The mixture will thicken, become smooth, and the final consistency will have minute lumps within the liquid. Preferably, before the pharmaceutical composition of the present invention is applied to the scalp, the bald spots are scrubbed with either pure lamb's wool or a soft-bristled brush made of animal hair. This cleanses the residue from the skin. The pharmaceutical composition of the present invention is then rubbed on the bald spots. After 25 minutes, the scalp is rinsed, removing any excess composition. This procedure is repeated daily for 15 days. The inventor has found that it usually takes three-fifteen days for pores to open and fifteen days to three months for fuzzy hair to appear. The inventor has found that it takes approximately one to six months for hair to grow to the point where it appears normal.
Inventors: Antoun; Jacques (3630 General de Gaulle Dr., New Orleans, LA 70114)
Appl. No.: 262953
U.S. Class: 424/642; 424/701
Intern'l Class: A61K 007/06
Field of Search: 424/642,70,658,659,660 514/880,881
124751 Mar., 1872 Lauer 424/642.
143133 Sep., 1873 Fehr 424/642.
415208 Nov., 1889 Johnson 424/642.
992937 May., 1911 Brodbeck 424/642.
2289125 Jul., 1942 Keil 424/642.
2652355 Sep., 1953 Ercoli 424/642.
4816254 Mar., 1989 Moss 424/642.
4911932 Mar., 1990 Clum et al. 424/642.
5015470 May., 1991 Gibson 424/70.
2653996 May., 1991 FR.
Attorney, Agent or Firm: Garvey, Smith, Nehrbass & Doody, L.L.C.
This is a Continuation-in-Part of U.S. patent application Ser. No. 07/863,795, filed Apr. 6, 1992, which is a Continuation-in-Part of U.S. patent application Ser. No. 07/609,392, filed Nov. 5, 1990, U.S. Pat. No. 5,102,916, which is a Continuation-in-Part of U.S. patent application Ser. No. 07/547,460, filed Jul. 3, 1990 now abandoned, all of which are hereby incorporated by reference.
1. A pharmaceutical composition comprising 0.143%-3.93% by weight starch, 1.00%-23.8% by weight of a compound comprising boron, 0.625%-15.8% by weight of a compound comprising zinc, and 69.4%-97.8% water.
2. The pharmaceutical composition of claim 1, wherein:
the composition is prepared by boiling a mixture comprising 0.143%-3.93% by weight starch, 1.00%-23.8% by weight of a compound comprising boron, 0.625%-15.8% by weight of a compound comprising zinc, and 69.4%-97.8% water for approximately 20 minutes while stirring continuously.
3. The pharmaceutical composition of claim 1, wherein:
the compound comprising boron is boric acid, and the compound comprising zinc is zinc oxide.
4. The pharmaceutical composition of claim 1, wherein:
the starch comprises 0.769%-2.73% by weight of the composition;
the compound comprising boron comprises 5.22%-17.1% by weight of the composition; and
the compound comprising zinc comprises 3.31%-11.2% by weight of the composition.
5. The pharmaceutical composition of claim 1, wherein:
the starch comprises 1.48%-1.86% by weight of the composition;
the compound comprising boron comprises 9.73%-12.1% by weight of the composition; and
the compound comprising zinc comprises 6.24%-7.82% by weight of the composition.
6. The pharmaceutical composition of claim 1, wherein:
the starch comprises about 1.64% by weight of the composition;
the compound comprising boron comprises 9.84% by weight of the composition; and
the compound comprising zinc comprises 6.56% by weight of the composition.
the compound comprising boron is boric acid; and
the compound comprising zinc is zinc oxide.
8. A pharmaceutical composition, consisting essentially of:
starch, a compound comprising boron, a compound comprising zinc, and water.
9. The pharmaceutical composition of claim 8, wherein:
the compound comprising boron is boric acid, and
10. The pharmaceutical composition of claim 8, consisting essentially of:
0.143%-3.93% by weight starch,
1.00%-23.8% by weight of the compound comprising boron,
0. 625%-15.8% by weight of the compound comprising zinc, and
11. The pharmaceutical composition of claim 8, consisting essentially of:
0.769%-2.73% by weight starch,
5.22%-17.1% by weight of the compound comprising boron,
3.31%-11.2% by weight of the compound comprising zinc, and
12. The pharmaceutical composition of claim 8, consisting essentially of:
6.24%-7.82% by weight starch,
9.73%-12.1% by weight of the compound comprising boron,
6.24%-7.82% by weight of the compound comprising zinc, and
13. A method of treating alopecia areata or male pattern baldness in a person in need of such treatment comprising:
topically administering to the person in need of treatment a therapeutically effective amount of a pharmaceutical composition comprising a compound comprising zinc, a compound comprising boron, and a suitable carrier for topical application of the pharmaceutical composition, the suitable carrier being a mixture of starch and water.
14. The method of claim 13, wherein the pharmaceutical composition comprises 0.143%-3.93% by weight starch, 1.00%-23.8% by weight of the compound comprising boron, 0.625%-15.8% by weight of the compound comprising zinc, and water.
15. The method of claim 13, wherein the pharmaceutical composition comprises 0.769%-2.73% by weight starch, 5.22%-17.1% by weight of the compound comprising boron, 3.31%-11.2% by weight of the compound comprising zinc, and water.
16. The method of claim 13, wherein the pharmaceutical composition comprises 1.48%-1.86% by weight starch, 9.73%-12.1% by weight of the compound comprising boron, 6.24%-7.82% by weight of the compound comprising zinc, and water.
18. The method of claim 13 wherein the pharmaceutical composition comprises a solution made by boiling the compound comprising zinc, the compound comprising boron, the starch, and the water.
about 30 ml of the pharmaceutical composition is administered topically at least five times per week for three weeks, and is rinsed off approximately 20-30 minutes after being administered topically.
20. A process of preparing a pharmaceutical composition by boiling a mixture comprising water and 0.143%-3.93% by weight starch, 1.00%-23.8% by weight of a compound comprising boron, 0.625%-15.8% by weight of a compound comprising zinc for approximately 20 minutes while stirring continuously.
23. A method of treating alopecia areata or male pattern baldness in a person in need of treatment consisting essentially of:
topically administering to the person in need of treatment an effective amount of the product of claim 21.
6 percent to 20 percent by volume of the product of claim 21 and the balance shampoo.
The present invention relates to pharmaceutical compositions for and methods of encouraging hair growth.
Hair loss occurs in many persons. Two relatively common causes of hair loss are male pattern baldness and alopecia areata. Alopecia areata is a disease affecting about two million people in the United States. It causes hair to fall out quickly, from scattered spots in the size a quarter to complete loss of all bodily hair, including the hair on the scalp. More information about alopecia areata can be obtained from the National Alopecia Areata Foundation (NAAF), P.O. Box 150760, San Rafael, Calif. 94915-0760, (415) 456-4644, Fax: (415) 456-4274. The NAAF publishes a bi-monthly newsletter.
The inventor of the present invention is aware of a commercially available pharmaceutical composition for encouraging hair growth--Rogaine.RTM. with minoxidil, commercially available from the Upjohn Company. However, Rogaine.RTM. is relatively expensive and has been shown to cause hair regrowth in only about 63% of the women who have tried it (as opposed to 39% of women in a placebo group). According to an August 1991 newspaper article, only 39 percent of men using Rogaine.RTM. in clinical trials either grew new hair or stopped losing hair after six to eight months on the drug.
Boric acid (H.sub.3 BO.sub.3) is a mild antiseptic. It also has been used as a germicide. Borax is sodium tetraborate (Na.sub.2 B.sub.4 O.sub.7) and is used as a laundry water softener. Its effect as a water softener is similar to that of ammonia.
The present invention comprises a pharmaceutical composition which has been found to encourage hair growth in humans. The pharmaceutical composition of the present invention consists essentially of water, a compound comprising boron, a compound comprising zinc, and starch ((C.sub.6 H.sub.10 O.sub.5).sub.x). The method of the present invention comprises applying a pharmaceutical composition containing a compound comprising boron, a compound comprising zinc, starch, and water to a person's scalp to treat alopecia areata or male pattern baldness.
One can mix the pharmaceutical composition of the present invention with commercially available shampoo for normal hair to help maintain the work of the pharmaceutical composition between treatments.
The pharmaceutical composition of the present invention comprises a zinc-containing compound and a boron-containing compound in a carrier suitable for topical application. Preferably, the zinc-containing compound is zinc oxide, the boron-containing compound is boric acid, and the carrier suitable for topical application is a mixture of starch and water.
The pharmaceutical composition used in the method of the present invention comprises 0.143%-3.93% by weight starch, 1.00%-23.8% by weight of the compound comprising boron, 0.625%-15.8% by weight of the compound comprising zinc, and water (as in Table 1 when zinc oxide and boric acid are used). More preferably, the pharmaceutical composition comprises 0.769%-2.73% by weight starch, 5.22%-17.1% by weight of the compound comprising boron, 3.31%-11.2% by weight of the compound comprising zinc, and water (as in Table 2 when zinc oxide and boric acid are used). Even more preferably, the pharmaceutical composition comprises 1.48%-1.86% by weight starch, 9.73%-12.1% by weight of the compound comprising boron, 6.24%-7.82% by weight of the compound comprising zinc, and water (as in Table 3 when zinc oxide and boric acid are used). Preferably, the compound comprising boron is boric acid, and the compound comprising zinc is zinc oxide.
Starch:      1-20    parts  0.143%-3.93%
Boric acid:  6-120   parts  1.00%-23.8%
Zinc oxide:  4-80    parts  .625%-15.8%
Water:       500     parts  69.4%-97.8%
Starch:      5-15    parts  .769%-2.73%
Boric acid:  30-90   parts  5.22%-17.1%
Zinc oxide:  20-60   parts  3.31%-11.2%
Water:       500     parts  75.2%-90.1%
Starch:      9-11    parts  1.48%-1.86%
Boric acid:  54-66   parts  9.73%-12.1%
Zinc oxide:  36-44   parts  6.24%-7.82%
Water:       500     parts  80.5%-83.5%
For example, the pharmaceutical composition of the present invention can comprise 10 parts by weight starch, 60 parts by weight boric acid, 40 parts by weight zinc oxide, and 500 parts by weight water. The dry ingredients (starch, boric acid, and zinc oxide) are mixed together, then the water is added. The mixture is boiled for about 20 minutes, stirring continuously. The mixture will thicken, become smooth, and the final consistency may have minute lumps within the liquid. When a greater quantity of the dry ingredients is used, it may be desirable to boil the mixture for fewer than 20 minutes.
Starch:        10 parts  1.64%
Boric acid:    60 parts  9.84%
Zinc oxide:    40 parts  6.56%
Water:         500 parts 81.97%
Total:         610 parts 100%
A pharmaceutical composition (Composition A) was made by mixing 10 grams of Argo.RTM. pure starch with 60 grams of boric acid obtained from Crystal, Canning Road, Seffner, Fla., and 40 grams of zinc oxide obtained from Humco Laboratory, Texarkana, Tex. 75501, then adding 500 milliliters of water and boiling for 20 minutes, stirring continuously. The composition thickened and became smooth. The final consistency was a colloidal suspension in liquid.
At the age of 8, F., a white male, was diagnosed with alopecia areata by a medical doctor in the United States. Around the age of 16, F. had an onset of alopecia areata, lost patches of hair on his head and on other parts of his body. Until the age of 19, F. was treated with cortisone injections, Retin A 0.05%, Dithrocreme 0.025%, and Rogaine.RTM., but with limited success. At the age of 20, F. was treated with Composition A, using the method of the present invention.
B., a white male, suffering from male pattern baldness, experienced severe thinning over approximately 50% of his scalp (top and rear). B. tried Dejojoba shampoo for six months, and Helsinkey shampoo for six months, but reported that the shampoos helped the hair grow very little.
Within three months, B. began to experience regrowth of hair on the affected area of his scalp. The new hair was initially fine, with thicker hair coming in after approximately seven months, the number of hairs per unit area in the affected areas increased to approximately 40%-50% of the rest of the scalp, up from about 10%.
R., a white male, began losing hair in spots at the age of 26. He lost approximately 20% of the hair on his scalp. He also lost hair on his chin and arm. He was diagnosed by a dermatologist as having alopecia areata, and the dermatologist prescribed Quaterzone. He used Quaterzone for three weeks, without success. He also tried AG Pro, an over-the-counter product, for about a month, but with little improvement.
One can mix the pharmaceutical composition of the present invention (such as Composition A) with commercially available shampoo for normal hair and use every day or every other day. In such a case, the pharmaceutical composition of the present invention preferably comprises 6% to 20% by volume of the mixture of shampoo and pharmaceutical composition. For example, most preferably one can mix 1 part by volume of the pharmaceutical composition of the present invention (such as Compositon A) with 4 parts by volume of commercially available shampoo for normal hair and use every day or every other day. This shampoo of the present invention should be left on the scalp or other affected area for 5-10 minutes, then rinsed off. The shampoo of the present invention can help maintain the work of the pharmaceutical composition between treatments. The shampoo to mix with Composition A could comprise, for example, Quantun shampoo for normal hair, Terma Fuse shampoo for normal hair, or Zachi shampoo for normal hair.